Showing 6901-6910 of 7494 results for "".
- Data Show Acne Patients Don't Understand Risks Associated with Antibiotic Treatmenthttps://practicaldermatology.com/news/data-show-acne-patients-dont-understand-risks-associated-with-antibiotic-treatment/2458805/Widespread and inappropriate use of antibiotics continues to be a problems in the US leading to antibiotic resistance issues. While most people understand how the overuse of antibiotics to treat viral infections contributes to this issue, according to Galderma, new data reveal that acne patients
- American Skin Association Medical Advisory Committee Names New Co-Chairhttps://practicaldermatology.com/news/american-skin-association-medical-advisory-committee-names-new-co-chair/2458807/American Skin Association (ASA) named current member Robert Modlin, MD as Co-Chair of its Medical Advisory Committee (MAC) alongside Dr. David Norris. Dr. Modlin is Chief of the Division of Dermatology and Professor of Dermatology in the Department of Medicine and Department of Microbiology, Immu
- ASDSA Patient Safety Hero Honorees Recognizedhttps://practicaldermatology.com/news/asdsa-patient-safety-hero-honorees-recognized/2458810/The American Society for Dermatologic Surgery Association (ASDS) announced its Patient Safety Hero Award recipients during the recent 2015 ASDS Annual Meeting in Chicago to recognize leaders who have taken an active role in the promotion and protection of patient safety in dermatologic procedures
- AMA Calls for Ban on Direct to Consumer Advertising of Prescription Drugs and Medical Deviceshttps://practicaldermatology.com/news/ama-calls-for-ban-on-direct-to-consumer-advertising-of-prescription-drugs-and-medical-devices/2458806/Physicians at the Interim Meeting of the American Medical Association (AMA) adopted new policy aimed at driving solutions to make prescription drugs more affordable. Physicians cited concerns that a growing proliferation of ads is driving demand for expensive treatments despite the clinic
- Ortek Therapeutics Files Patent Applications for New Microbiome to Reduce S. Aureus Proliferationhttps://practicaldermatology.com/news/ortek-therapeutics-files-patent-applications-for-new-microbiome-to-reduce-s-aureus-proliferation/2458808/Stony Brook University and Ortek Therapeutics, Inc. filed two patent applications in the United States and internationally for nutrient based compositions utilizing innovative microbiome technology. Developed at Stony Brook University, these compositions have been exclusively licensed to Ortek as
- ASDS Awards 10 Clinical Research Grantshttps://practicaldermatology.com/news/asds-awards-10-clinical-research-grants/2458811/The American Society for Dermatologic Surgery (ASDS) has awarded a total of $96,000 to 10 new clinical research projects through its Cutting Edge Research Grant program. This year’s research projects will focus on topics ranging from examining the effectiveness of specific lasers on surgica
- GSK: Positive Phase 3 Results for Benlysta® In Patients with Systemic Lupus Erythematosushttps://practicaldermatology.com/news/gsk-positive-results-phase-3-results-for-benlysta-in-patients-systemic-lupus-erythematosus/2458812/Results from the BLISS-SC Phase 3 pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) show that Benlysta®(belimumab) 200mg administered weekly via subcutaneous injection plus
- Cosmetic Bootcamp University Exceeds Goalshttps://practicaldermatology.com/news/cosmetic-bootcamp-university-a-success/2458815/Now completing its session in Philadelphia, the Cosmetic Bootcamp University session has exceeded goals, organizers report. Cosmetic Bootcamp seeks to improve patient outcomes in a manner not possible at other meetings by focusing on core specialists in dermatology, plastic surgery, op
- Diplomat Pharmacy to Dispense Cotellic®https://practicaldermatology.com/news/diplomat-pharmacy-to-dispense-cotellic/2458816/Diplomat Pharmacy, Inc. will dispense Cotellic® (cobimetinib) in combination with the BRAF inhibitor Zelboraf® (vemurafenib) to treat patients with advanced melanoma that is unrespectable or metastatic. The com
- LEO Pharma to Acquire Global Dermatology Portfolio from Astellashttps://practicaldermatology.com/news/leo-pharma-to-acquire-global-dermatology-portfolio-from-astellas/2458818/LEO Pharma A/S and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million. Under the terms of the agreement, the assets and associated respon